Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 232 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2014', provides an overview of the Takeda Pharmaceutical Company Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Takeda Pharmaceutical Company Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Takeda Pharmaceutical Company Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Takeda Pharmaceutical Company Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Takeda Pharmaceutical Company Limited's pipeline products

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Takeda Pharmaceutical Company Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Takeda Pharmaceutical Company Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Takeda Pharmaceutical Company Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Takeda Pharmaceutical Company Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Takeda Pharmaceutical Company Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Takeda Pharmaceutical Company Limited Snapshot 7
Takeda Pharmaceutical Company Limited Overview 7
Key Information 7
Key Facts 7
Takeda Pharmaceutical Company Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Takeda Pharmaceutical Company Limited - Pipeline Review 16
Pipeline Products by Stage of Development 16
Pipeline Products - Monotherapy 17
Pipeline Products - Combination Treatment Modalities 18
Pipeline Products - Partnered Products 19
Pipeline Products - Out-Licensed Products 21
Takeda Pharmaceutical Company Limited - Pipeline Products Glance 23
Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products 23
Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products 25
Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 27
Takeda Pharmaceutical Company Limited - Drug Profiles 30
(alogliptin benzoate + metformin hydrochloride) 30
(alogliptin benzoate + pioglitazone hydrochloride) 32
(azilsartan kamedoxomil + chlorthalidone) 34
alogliptin benzoate 35
ceftaroline fosamil 38
fomepizole 40
haemophilus influenzae type b vaccine 41
ramelteon 42
roflumilast 43
trelagliptin 46
vedolizumab 48
vonoprazan 50
azilsartan kamedoxomil 52
febuxostat XR 54
immune globulin (human) 55
lubiprostone 57
lurasidone hydrochloride 59
motesanib diphosphate 61
trebananib 65
vortioxetine hydrobromide 68
AM-4 70
DSM-265 71
MLN-1202 72
namilumab 73
norovirus vaccine (bivalent) 74
relugolix 75
TAK-003 76
TAK-114 78
TAK-361S 80
fulranumab 81
INV-21 83
ITI-214 84
MLN-3126 85
rasagiline mesylate 86
TAK-058 87
TAK-063 88
TAK-079 89
TAK-137 90
TAK-233 91
TAK-272 92
TAK-935 93
tedatioxetine 94
BTZO-15 96
BTZO-2 97
chikungunya vaccine 98
ELQ-300 99
human papillomavirus vaccine 100
influenza vaccine 101
Influenza VLP Vaccine 102
japanese encephalitis vaccine 103
mapatumumab 104
MVA Vaccine 107
respiratory syncytial virus vaccine 108
RUSKI-43 109
Small Molecule Dual HER2/EGFR Inhibitor for Cancer 111
Small Molecule to Activate Glucokinase for Type 2 Diabetes 112
Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain 113
Small Molecule to Agonize GPR52 for Psychiatry Disorders 114
Small Molecule to Antagonize Androgen Receptor for Prostate Cancer 115
Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension 116
Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder 117
Small Molecule to Antagonize PDGFR and VEGFR-2 for Cancer 118
Small Molecule to Inhibit FAAH for Pain 119
Small Molecule to Inhibit Farnesoid X Receptor for Dyslipidemia 120
Small Molecule to Inhibit MCHR1 for Obesity 121
Small Molecule to Inhibit Serotonin-Norepinephrine-Dopamine Reuptake for Depression 122
Small Molecule Triple Reuptake Inhibitors for Depression 123
Small Molecules for Cognitive Impairment Associated with Schizophrenia 124
Small Molecules for Parkinson's Disease 125
Small Molecules to Agonize GPR119 for Type II Diabetes 126
Small Molecules to Antagonize c-Met and VEGFR2 for Cancer 127
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity 128
Small Molecules to Inhibit DPP-IV for Diabetes 129
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma 130
Small Molecules to Inhibit PARP-1 for Cancer 131
Stem Cell Therapy for Muscular Dystrophy 132
Subunit Vaccine for Rotavirus Infections 133
T-1840383 134
T-3256336 135
TAK-075 136
TAK-480 137
TAK-632 138
Y-443 139
Antibodies for Undisclosed Indication 140
Drug to Inhibit PDE for Leishmaniasis and Trypanosomiasis 141
Monoclonal Antibody Conjugate for Cancer 142
Small Molecule for Diabetes and Obesity 143
Small Molecule for Undisclosed Indication 144
Small Molecule to Inhibit Arginine Methyltrasferase for Cancer 145
Small Molecule to Inhibit FAK for Cancer 146
Small Molecule to Inhibit HDAC6 147
Small Molecule to Inhibit HER2 and EGFR for Cancer 148
Small Molecule to Inhibit IAP for Cancer 149
Small Molecules for Malaria 150
Small Molecules for Tuberculosis 151
Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 152
Small Molecules to Inhibit CENP-E for Cancer 153
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Cancer 154
Small Molecules to Inhibit MMP-13 for Osteoarthritis 155
Y-142 156
Takeda Pharmaceutical Company Limited - Pipeline Analysis 157
Takeda Pharmaceutical Company Limited - Pipeline Products by Target 157
Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 161
Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type 162
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action 163
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 167
Takeda Pharmaceutical Company Limited - Dormant Projects 200
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 202
Discontinued Pipeline Product Profiles 203
Takeda Pharmaceutical Company Limited - Company Statement 213
Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 214
Head Office 214
Other Locations & Subsidiaries 214
Takeda Pharmaceutical Company Limited - Key Manufacturing Facilities 222
Appendix 223
Methodology 223
Coverage 223
Secondary Research 223
Primary Research 223
Expert Panel Validation 223
Contact Us 224
Disclaimer 224

List of Tables
Takeda Pharmaceutical Company Limited, Key Information 15
Takeda Pharmaceutical Company Limited, Key Facts 15
Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2014 19
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2014 24
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2014 25
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2014 26
Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2014 27
Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2014 28
Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2014 29
Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2014 30
Takeda Pharmaceutical Company Limited - Pre-Registration, 2014 31
Takeda Pharmaceutical Company Limited - Phase III, 2014 32
Takeda Pharmaceutical Company Limited - Phase II, 2014 33
Takeda Pharmaceutical Company Limited - Phase I, 2014 34
Takeda Pharmaceutical Company Limited - Preclinical, 2014 35
Takeda Pharmaceutical Company Limited - Discovery, 2014 37
Takeda Pharmaceutical Company Limited - Pipeline by Target, 2014 166
Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2014 169
Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2014 170
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2014 172
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2014 175
Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2014 208
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2014 210
Takeda Pharmaceutical Company Limited, Subsidiaries 222
Takeda Pharmaceutical Company Limited, Key Manufacturing Facilities 230